Protillion Biosciences, a Burlingame, CA-based biotech company, raised $18M in Series A funding.
The round was led by ARCH Venture Partners and Illumina Ventures.
The company intends to use the funds to scale its hardware infrastructure and development teams.
Led by co-founder and CEO Curtis Layton, Ph.D., Protillion Biosciences is a Stanford University spinout commercializing technology for therapeutic antibody and binder discovery. The company’s platform enables its commercial drug discovery partners to perform quantitative analysis on complete protein libraries, producing actionable insights in days. Protillion’s proprietary technology can generate and analyze massive experimental datasets at perfect amino acid resolution, enabling novel machine-learning approaches to antibody and binder discovery.
Launched in 2019, the technology was developed by Dr. Curtis Layton in the Stanford University laboratory of co-founder William Greenleaf, Ph.D. In addition, the co-founder of Protillion includes David Walt, Ph.D., of the Wyss Institute at Harvard University, Brigham and Women’s Hospital, and Harvard Medical School, who will serve on Protillion’s Board of Directors.
FinSMEs
19/12/2022